The Asia Pacific Leaders Malaria Alliance (APLMA) and Asia Pacific Malaria Elimination Network (APMEN) welcomes the recently approved (14 March 2022) use of single-dose tafenoquine by the Australian Therapeutic Goods Administration (TGA) for the prevention of relapsing Plasmodium vivax (P. vivax) malaria in children aged 2 years and above.
The Asia Pacific Leaders Malaria Alliance (APLMA) and Asia Pacific Malaria Elimination Network (APMEN) welcomes the recently approved (14 March 2022) use of single-dose tafenoquine by the Australian Therapeutic Goods Administration (TGA) for the prevention of relapsing Plasmodium vivax (P. vivax) malaria in children aged 2 years and above.